Cambridge, United Kingdom and Boston, Massachusetts — August 5, 2025 — Leads & Copy — CellCentric, a privately held biotechnology company, announced its senior management team will participate in several upcoming investor conferences to highlight the company’s clinical progress with inobrodib, which will be entering a potentially registration enabling study later this year.
Upcoming appearances include Oppenheimer & Co.’s 2025 Biotech in the Berkshires, Citi’s 2025 Biopharma Back to School Conference, the 2025 Wells Fargo Healthcare Conference, the Cantor Global Healthcare Conference, the Morgan Stanley Health Care Conference, and the BofA Securities Healthcare Trailblazers Private Company Conference.
Inobrodib is a potential new treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, including MYC and IRF4. It has been evaluated in over 400 patients to date and has a favourable safety and tolerability profile. Clinical activity has been seen in multiple settings, both solid tumour and hematologic malignancies.
For more information or to request a meeting, please contact: IR@cellcentric.com
CellCentric is a privately held biotechnology company advancing inobrodib, a first-in-class, orally bioavailable p300/CBP inhibitor. Inobrodib is in a Phase II clinical trial for patients with relapsed/refractory multiple myeloma, with additional indications under consideration.
